Neo Kuma Ventures is a new venture fund in London that s just for investing in psychedelics.
Psychedelics are mind-altering substances, like the psilocybin found in magic mushrooms.
Early research suggests that psychedelics could be used to treat health conditions, like mental illnesses resistant to conventional treatments.
Psychedelics is an emerging industry worldwide, separate to cannabis. Canada, the US and Europe are frontrunners.
Neo Kuma s 35-year-old co-founder shared her strategy for an emerging and risky field.
Clara Burtenshaw had a personal interest in psychedelics that s now become her job. The 35-year-old lawyer has just started a venture fund in the UK, devoted to investing in psychedelics.
Britain s first psychedelic healthcare fund ifamagazine.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ifamagazine.com Daily Mail and Mail on Sunday newspapers.
17 Dec 2020 Share:
More and more revolutionary mind-altering medicines and treatments based on active ingredients previously spurned as street drugs, such as ketamine and psilocybin (magic mushrooms), are gaining acceptance with regulators. Clinical trials show psychedelics have huge potential to help people with treatment resistant mental illnesses including depression, addiction, anxiety and inflammation. So, with the launch of its first investment fund, will the psychedelic healthcare sector run at the heels of the medicinal cannabis industry and enable Europe to become the new hub of a burgeoning market sector?
The UK s first investment fund dedicated solely to psychedelic healthcare has launched.